Aramchol Meglumine
NASH and Fibrosis
Key Facts
About Galmed Pharmaceuticals
Galmed Pharmaceuticals' mission is to develop 'lifetime medicine' for metabolic and inflammatory diseases, leveraging its proprietary Fatty Acid Bile Acid Conjugate (FABAC) platform. Its primary achievement is advancing Aramchol, a liver-targeted SCD1 modulator, into a global Phase 3 registrational trial (ARMOR) for NASH with fibrosis, following promising Phase 2b data. The company's strategy involves executing the ARMOR trial while exploring strategic options to unlock value from its clinical asset and preclinical pipeline. However, its path is marked by significant financial constraints and intense competition in the NASH landscape.
View full company profile